ProPhase Labs (PRPH) said late Thursday it priced an underwritten offering of 4.17 million shares of its common stock, targeting gross proceeds of about $3 million.
Shares slumped past 45%, with intraday trading volume at over 2.1 million compared with a daily average of about 34,000.
Evolent Health (EVH) shares plunged amid heavy trading after Truist Securities cut its price target on the company's stock following Q3 results that fell short of market expectations.
Oppenheimer also adjusted Evolent's price objective to $34 from $45 while maintaining its outperform rating.
Shares of Evolent sank 43% as intraday trading volume jumped to more than 14.4 million versus a daily average of about 2.1 million.
Maravai Lifesciences (MRVI) said late Thursday it agreed to buy Officinae Bio's DNA and RNA business. Financial terms of the deal were not disclosed.
Shares of Maravai slumped 39% as intraday trading volume climbed to over 8.5 million from the stock's daily average of about 1.9 million.
Price: 0.78, Change: -0.65, Percent Change: -45.24
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。